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Abstract
Congenital dyserythropoietic anemia type II or HEMPAS (hereditary erythroblastic multinuclearity with positive acidified
serum lysis test) is a genetic anemia in humans caused by a glycosylation deficiency. Erythrocyte membrane glycoproteins,
such as band 3 and band 4.5, which are normally glycosylated with polylactosamines lack these carbohydrates in HEMPAS.
Polylactosamines accumulate as glycolipids in HEMPAS erythrocytes. Analysis of N-glycans from HEMPAS erythrocyte
membranes revealed a series of incompletely processed N-glycan structures, indicating defective glycosylation at
N-acetylglucosaminyltransferase II (GnT-II) and/or K-mannosidase II (MII) steps. Genetic analysis has identified two
cases from England in which the MII gene is defective. Mutant mice in which the MII gene was inactivated by homologous
recombination resulted in a HEMPAS-like phenotype. On the other hand, linkage analysis of HEMPAS cases from southern
Italy excluded MII and GnT-II as the causative gene, but identified a gene on chromosome 20q11. HEMPAS is therefore
genetically heterogeneous. Regardless of which gene is defective, HEMPAS is characterized by incomplete processing of
N-glycans. The study of HEMPAS will identify hitherto unknown factors affecting N-glycan synthesis. ß 1999 Published
by Elsevier Science B.V. All rights reserved.
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1. Introduction
Congenital dyserythropoietic anemia (CDA) is a
group of inherited disorders characterized by an in-
e¡ective erythropoiesis, bone marrow erythroid mul-
tinuclearity, and secondary tissue siderosis [1^4]. In
1968, Heimpel and Wendt classi¢ed CDA into three
types (Table 1) [2]. CDA type II is the most common
CDA and is also called HEMPAS, since Crookston
characterized this disease as hereditary erythroblastic
multinuclearity with positive acidi¢ed serum lysis test
[3]. This chapter covers only CDA type II (CDA-II,
CDAN2 or HEMPAS), but those interested in other
types of CDAs are encouraged to read references
cited [5^8].
As described below, HEMPAS is a biochemically
homogeneous entity characterized by incomplete
processing of N-glycans [9^11]. Genetically, however,
HEMPAS is heterogeneous [12]. Clinical variations
may be linked to genetic heterogeneity. This reviewr
describes symptoms and biochemical and genetic
characterizations of HEMPAS disease and discusses
unsolved problems and future prospects regarding
this disease.
2. Occurrence
HEMPAS is an autosomal recessive anemia in hu-
mans. Parents and some siblings of HEMPAS
patients are clinically normal but are heterozygous
carriers of the defective gene. Both sexes are equally
a¡ected. Conservative numbers of patients reported
in the literature are 130 [8], although as many as
300 cases may exist [11]. HEMPAS patients have
been found on all continents and in a variety of
races. As is the case with other rare recessive genetic
diseases, HEMPAS patients are found more often in
areas where people have a high incidence of inter-
marriage.
Literature on HEMPAS suggests that the disease
is often asymptomatic and is therefore not as rare as
hitherto believed. This disease may become clinically
apparent when another hereditary or acquired dis-
ease occurs. For example, de¢ciencies in glutathione
reductase, acetylcholine esterase, and adenyl cyclase
have been reported in association with HEMPAS
[13]. HEMPAS patients are associated with glucose-
6-phosphate dehydrogenase de¢ciency [14,15], abnor-
mal hemoglobin [16], genetically determined a L-lip-
oprotein anemia [17], or ectodermal dysplasia [18].
HEMPAS cases accompanying hairy cell leukemia
[19], acquired tocopherol de¢ciency [4,20], and ac-
quired aplastic crisis caused by infection with parvo-
virus or other pathogens [21] indicate that incidence
of acquired disease can result in the manifestation of
HEMPAS.
Table 1
Three types of CDAs
Features Type I Type II Type III
No. of patients [7] 70 130 40
Anemia Mild to moderate Mild to severe Mild to moderate
Bone marrow V5% binucleated
chromatin bridge
10^40% bi- and multinucleated 10^40% multinucleated
gigantoblasts
Inheritance Recessive Recessive Dominant
Primary defect Unknown Defect in N-glycan synthesis Unknown
Defective genes and chromosome
localizationa
CDAN1 (15q15.1^3)
[54]
MII (5q25) [43,44]; CDAN2 (20q11.2)
[47] ; others [11]
CDAN3 (15q21^25) [55]
aEach protein encoded by CDAN1, CDAN2 and CDAN3 genes has not been identi¢ed.
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3. Symptoms
HEMPAS patients su¡er from a life-long anemia.
Jaundice is common. In most cases the magnitude of
anemia is mild; however there are severely a¡ected
patients who require constant care and frequent
transfusions.
The most striking diagnostic feature of HEMPAS
is abnormal multinucleated erythroblasts in the bone
marrow [1^5]. While immature erythroblasts appear
normal, 5^40% of mature erythroblasts are multi-
nucleated (Fig. 1). Multinuclearity may be caused
by a failure of cell division. Erythrocytes released
to the peripheral blood are short-lived: 7^34 days
in HEMPAS versus 100 days in normal adults. The
spleen may be the principal site of erythrocyte de-
struction, leading to splenomegaly in HEMPAS. Sur-
gical removal of the spleen (splenectomy) often alle-
viates the anemia.
Also common are liver hemosiderosis and cirrhosis
[22^24]. Although hemosiderosis is seen in other ane-
Fig. 1. Bone marrow aspirate from a HEMPAS patient show-
ing multinucleated erythroblasts.
Fig. 2. Biosynthesis of N-glycans and HEMPAS defect. In the Golgi, high mannose oligosaccharides attached to a nascent glycopro-
tein are processed to trimannosyl oligosaccharide by MII. Trimannosyl oligosaccharide normally receives GlcNAc (Gn) due to GnT-II
action and is processed to a complex type oligosaccharide or further elongated to polylactosamines. In HEMPAS, a genetic defect of
MII results in blockage of N-glycan processing at the MII step, leading to the accumulation of pentamannosyl hybrid type oligosac-
charide. However, in some HEMPAS patients, accumulation of trimannosyl hybrid type oligosaccharide (boxed area in the ¢gure) is
detected, suggesting an as yet unknown genetic defect at a locus other than the MII gene disrupts glycosylation.
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mias, the magnitude of hemosiderosis is remarkable
although the patient’s circulation does not show iron
overload [23]. Some HEMPAS patients need to have
blood withdrawn in order to prevent hemosiderosis
and cirrhosis.
The incidence of diabetes is high among HEMPAS
patients. The cause of diabetes is an interesting ques-
tion as incomplete glycosylation (see below) may re-
sult in exposure of otherwise cryptic antigens result-
ing in autoimmunity against pancreas cells. A
transient autoimmune reaction to erythrocyte RhD
antigen was also reported in one HEMPAS case [25].
Severe cases of HEMPAS show mental and sen-
sory abnormalities [3,4]. It is not clear at this time
whether the neuronal symptoms are directly caused
by a glycosylation defect. As reported by Schachter
[26^28], glycosylation de¢ciency syndrome (CDGS)
type II, which is caused by a GnT-II defect, shows
severe neuronal abnormalities. As GnT-II catalyzes
the step following MII in N-glycan synthesis (Fig. 2),
the occurrence of neuronal abnormalities in some
HEMPAS patients suggests that phenotypes appear-
ing in extreme cases of HEMPAS may resemble
CDGS type II.
4. Glycosylation defect in HEMPAS
Pioneering studies by Heimpel [2], Crookston and
Vervirgen [3,4] suggested that HEMPAS is caused by
abnormal organization of erythrocyte membranes. In
1975, Joseph and Gockerman [29,30] found an ab-
normality in the glycolipid pro¢le of HEMPAS er-
ythrocyte membranes. Their analysis showed an in-
crease in lacto-N-triaosylceramide and lacto-N-
tetraosylceramide in HEMPAS. Such an abnormal
glycolipid pro¢le has been consistently detected in
later studies [31,32] (Fig. 3). On the other hand, in
1977 Anselstetter reported that band 3 glycoprotein
from HEMPAS erythrocytes migrates slightly faster
than the normal band 3 [33]. Such a shift in the
apparent molecular mass of band 3 glycoprotein
has been detected in all HEMPAS cases, whereas it
has not been found in the erythrocytes from patients
with other hematological disorders [34^38]. Careful
proteolytic analysis of HEMPAS band 3 excluded
the possibility of peptide deletion, and the data sug-
gested underglycosylation of HEMPAS band 3 [34].
Fig. 3. Abnormal glycosylation of glycoproteins and glycolipids
in HEMPAS erythrocyte membranes. (A) Fluorogram of eryth-
rocyte membrane components resolved by sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis. Galactose and N-acetyl-
galactosamine residues on the erythrocyte surface were labeled
by the galactose oxidase-Na[B3H]4 method. Surface labeled cells
were then treated with endo-L-galactosidase. In normal erythro-
cytes, band 3 and band 4.5 glycoproteins are labeled (left in 1)
and the labels disappear after endo-L-galactosidase treatment
(right lane in 1) because these glycoproteins are glycosylated by
polylactosamines. Lanes 2 and 3 are parents of the HEMPAS
patients. Parents are clinically normal, but they are hetero-
zygous for the HEMPAS defect. Note that the parents showed
a pro¢le similar to that of normal. In contrast, two HEMPAS
children (lanes 4 and 5) showed an abnormal pro¢le: band 3
and band 4.5 are not glycosylated, while polylactosamines ap-
pear in the low molecular weight region (shown by arrows).
These polylactosamines characteristic to HEMPAS are polylac-
tosaminyl ceramide. Thus it appears that a genetic factor in
HEMPAS blocks the formation of polylactosamines on the gly-
coprotein acceptors, and shifts these carbohydrates to the lipid
acceptors. (B) Thin-layer chromatogram showing glycolipids
from normal and HEMPAS erythrocyte membranes. The sam-
ples were prepared from the same HEMPAS family presented
in A. Major glycolipids in normal erythrocytes (lane 1) are glo-
bo tri- and tetraosylceramides (Gb3, Gb4). Parents of HEM-
PAS children who are heterozygous for the HEMPAS defect
show a pattern almost identical to the normal. In contrast, gly-
colipids from HEMPAS patients show an accumulation of the
lacto-series glycolipids (Lc3, Lc4).
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Surface labeling and endo-L-galactosidase treat-
ment analysis demonstrated that both band 3 and
band 4.5 glycoproteins, which normally are glyco-
sylated with polylactosamines, virtually lack polylac-
tosamines in HEMPAS [37] (Fig. 3). Absence of
polylactosamines in HEMPAS erythrocyte glyco-
proteins was also demonstrated by Western blot
using tomato lectin [27]. Furthermore, in HEMPAS
erythrocytes polylactosamines accumulate as poly-
lactosaminyl ceramides [32,37,39]. Thus it appears
that a genetic factor in HEMPAS blocks the glyco-
sylation of glycoprotein acceptors and shifts polylac-
tosamines to lipid acceptors, resulting in an increase
in the lacto-series glycolipids including polylactos-
aminyl ceramides (Figs. 3 and 4).
Structural analysis of HEMPAS band 3 carbohy-
drates showed the presence of the so-called hybrid
type oligosaccharides in addition to complex type
oligosaccharides [40^42]. However, it was di⁄cult
to predict at which step the glycosylation stops solely
by determining the N-glycan pro¢les of HEMPAS
band 3. Nevertheless, the results suggested disruption
of N-glycan synthesis near the N-acetylglucosaminyl-
transferase II (GnT-II) and K-mannosidase II (MII)
steps (Fig. 2). These analyses also showed that the
glycosylation defect is leaky in HEMPAS and sug-
gested the existence of an isozyme of MII, which
eventually led to identi¢cation of a gene encoding
an MII-like enzyme, K-mannosidase IIx (MIIx) [43].
Analysis of N-glycan structures of transferrin and
K1-acid glycoprotein from HEMPAS patients sera
revealed that these glycoproteins have hybrid and
high mannose type oligosaccharides [44]. Because
these serum glycoproteins are synthesized in hepato-
cytes, it is evident that the glycosylation defect is not
restricted to the erythroid lineage. This evidence is
Fig. 4. Erythrocyte membrane glycoproteins and glycolipids in normal and HEMPAS. In normal erythrocyte, glycoproteins, such as
band 3, are glycosylated by polylactosamines. Although polylactosaminyl ceramides are present in small quantity in normal erythro-
cytes, the majority of erythrocyte glycolipids belong to the globo-series with short carbohydrate chains. In HEMPAS, glycoproteins
lack polylactosamines whereas lacto-series glycolipids including polylactosaminylceramides are accumulated.
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surprising because serum glycoproteins need to be
fully sialylated, otherwise asialo- and agalacto-glyco-
proteins are recognized by hepatic lectin and are
cleared from the circulation. In fact, a signi¢cant
part of transferrin puri¢ed from HEMPAS patient
sera was quickly cleared from the circulation by the
liver upon injection into a rat. The quantity of in-
completely processed serum glycoproteins which
should be digested in the lysosomes in the liver is
overwhelming in HEMPAS patients. It seems un-
avoidable that HEMPAS patients develop cirrhosis.
5. Primary defect and genetic heterogeneity of
HEMPAS
Clinical variations of HEMPAS suggested that this
disease is a genetically heterogeneous collection, and
recent analysis has indeed indicated that this is the
case.
Patient GC was the ¢rst HEMPAS case identi¢ed
as being defective in the MII gene. GC showed ac-
cumulation of hybrid type oligosaccharides with the
core structure Gn1M5Gn2, the substrate for the Gol-
gi N-glycan processing enzyme MII. An enzyme ac-
tivity assay showed a signi¢cant reduction in mem-
brane bound MII activity. Northern analysis
revealed that lymphoblasts from GC express the
MII transcript at less than 10% of normal levels
[42]. Recently another HEMPAS case (LF) having
mutations in the coding region of the MII gene has
been identi¢ed. LF is a compound heterozygous pa-
tient: one allele has a deletion and the other has an
insertion (T. Akama et al., unpublished). Both the
deletion and insertion occur at exon-intron junctions,
suggesting that mutations in the LF MII gene lead to
alternative splicing of each allele. GC and LF are of
British and Irish descents, respectively.
While we could identify HEMPAS cases with de-
fective MII genes, the gene defect of HEMPAS pa-
tients from southern Italy remained undetermined.
Northern analysis or reverse transcriptase^polymer-
ase chain reaction followed by sequencing of GnT-II
and MII genes failed to show a mutation in many
HEMPAS cases (Fukuda and Schachter, unpub-
lished). On the other hand, Iolascon’s group em-
ployed linkage analysis using sets of microsatellite
markers £anking MII, MIIx and GnT-II genes. Their
data excluded linkage to all three genes in HEMPAS
cases from southern Italy [45]. Furthermore, they
identi¢ed the HEMPAS causative gene (CDAN2)
on chromosome 20q11.2 [46]. It is predicted that a
YAC clone containing the identi¢ed region will even-
tually lead to identi¢cation of the protein encoded by
the CDAN2 gene.
In addition to MII and CDAN2 defects, linkage
analysis showed that two families from southern
Italy did not have defects in MII, MIIx, GnTII or
CDAN2 [12].
The question remains how a defect in a gene en-
coding a protein other than a glycosylation enzyme
results in disruption of N-glycan synthesis at the
GnT-II and MII steps. One possibility is that the
gene encodes a transcription factor regulating expres-
sion of GnT-II or MII [11,45,46]. However, North-
ern blot analysis did not show reduction of GnT-II
or MII transcripts in southern Italy HEMPAS cases
(Fukuda, unpublished). An alternative possibility is
that a defect exists in a Golgi or cytoplasmic protein
regulating membrane tra⁄cking and that this defect
a¡ects glycosylation. Biochemical similarities among
HEMPAS patients suggest that di¡erent gene prod-
ucts a¡ect the same biochemical pathway. Further
studies on HEMPAS will provide new information
about factors a¡ecting N-glycan biosynthesis.
6. Animal model of HEMPAS
Recent advances in transgenic animal technology
allow the creation of mutant animals that mimic hu-
man genetic diseases. Using this technology, a mu-
tant mouse in which the MII gene is inactivated by
homologous recombination has been created [47].
MII null mice appear normal at birth and grow to
adulthood. There are no obvious deformities or life
threatening defects in these mice. MII null mice,
however, show various signs of anemia and remark-
able splenomegaly. The peripheral blood contains
immature erythrocytes or reticulocytes. Lectin blots
of erythrocyte membrane proteins con¢rmed a lack
of complex type N-glycans in MII null mice, presum-
ably due to the shift of N-glycan synthesis to high
mannose type and hybrid type oligosaccharides.
Structural analysis using spleen cells and ¢broblasts
indicated a reduced amount of complex type N-gly-
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cans in MII null mice, suggesting the presence of an
alternate pathway which bypasses the MII step. The
mutant erythrocytes agglutinate strongly with anti-i
antibodies, a condition which resembles HEMPAS
erythrocytes. An increase in lacto-series glycolipids,
characteristic of HEMPAS erythrocytes, was also
seen in MII null mice.
There are subtle di¡erences between the pheno-
types of MII null mice [47] and the symptoms of
HEMPAS [1^4]. For example, MII mutant mice do
not show multinucleated erythroblasts. Diabetes, gall
stones and neuronal anomalies were also not de-
tected in MII null mice.
Studies of gene knock-out mice by others indicated
that phenotypes appearing in a mutant mouse are
not always identical to what is seen in a human dis-
ease. This is because of signi¢cant di¡erences be-
tween human and mouse [48,49]. The lack of multi-
nucleated erythroblasts in MII null mice could be
due to quantitative di¡erences in polylactosamines
in erythroblasts between humans and mice. Besides
species di¡erence, it is known that the genetic back-
ground of mice a¡ects phenotypes observed in mu-
tants. Since HEMPAS cases show clinical heteroge-
neity [3,4] and there are many cases associated with
other genetic diseases [11,14^18], it is likely that the
MII defect could produce a severe phenotype if
additional defects co-existed in MII null mice. Con-
sidering species di¡erences and factors potentially
a¡ecting the phenotypes in the mutant mice, dysery-
thropoiesis exhibited by MII null mice supports the
hypothesis that defective N-glycan synthesis at the
MII step results in HEMPAS.
7. Unsolved problems and future prospects
Phenotypes appearing in MII null mice support
the link between genetic defects of MII and HEM-
PAS [47]. However, cases in which the primary defect
is found in the MII gene appear to be limited to the
HEMPAS patients from England. Majority of
HEMPAS patients from southern Italy are caused
by a mutation in the CDAN2 gene on chromosome
20q11. The nature of the protein encoded by
CDAN2 is unknown. In addition, there are some
cases which exclude all these candidate genes.
Besides typical HEMPAS cases, variants are
known [50^53]. These variants may be extreme cases
caused by various mutations of the same gene. Be-
cause symptoms of HEMPAS are more severe when
other genetic and acquired illnesses are present, it is
possible that unde¢ned genetic factors a¡ect HEM-
PAS, giving variant phenotypes. It is also possible
that genes other than MII and CDAN2 are involved
in the variants [11].
In our earlier studies, GnT-II was proposed to be
defective in some HEMPAS cases [41]. However, lat-
er genetic analysis failed to identify a GnT-II defect
in HEMPAS. It became clear that the GnT-II defect
results in CDGS type II but not HEMPAS [27,28].
We cannot, however, exclude the possibility that the
HEMPAS gene defect indirectly a¡ects GnT-II activ-
ity, which causes incomplete blockage of N-glycan
processing and results in phenotypes similar to those
seen in MII gene defects. The evidence that polylac-
tosamines are formed in CDGS type II erythrocyte
glycoproteins seems paradoxical since in some HEM-
PAS patients the erythrocyte membranes accumu-
lated the same trimannosyl hybrid oligosaccharide
as that due to the GnT-II defect. It seems that fac-
tors other than enzymes and acceptor oligosaccha-
ride structures are involved in polylactosamine syn-
thesis. The study of HEMPAS will identify hitherto
unknown factors a¡ecting N-glycan and polylactos-
amine synthesis.
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